Landyshev Iu S, Grigorenko A A, Tikhonova G A
Ter Arkh. 2002;74(8):45-8.
Clinical and experimental validation of liposomal therapy with hydrocortisone as a perspective treatment of bronchial asthma (BA).
Multistage trials of the liposomal treatment were made on 96 animals and in 137 BA patients. The decision on this treatment was based on the activity of bronchial inflammation and absence of contraindications. Liposomes were introduced endobronchially after a session of jet high-frequency artificial lung ventilation.
Clinical endoscopic remission was achieved shortly after the treatment start in most of the patients. External respiration function and gas composition of blood improved, concentration of malonic dialdehyde lowered while catalase and glucose-6-phosphate dehydrogenase activity enhanced, inhalation sympathomimetics requirement reduced.
Clinicomorphological and laboratory evidence obtained indicate high efficiency of liposomal therapy as an alternative to basic treatment of BA.
对以氢化可的松脂质体疗法作为支气管哮喘(BA)的一种潜在治疗方法进行临床和实验验证。
对96只动物和137例BA患者进行了脂质体治疗的多阶段试验。该治疗方案的确定基于支气管炎症的活动情况以及无禁忌症。在进行一次喷射高频人工肺通气后,通过支气管内注入脂质体。
大多数患者在治疗开始后不久即实现了临床内镜缓解。外部呼吸功能和血液气体成分得到改善,丙二醛浓度降低,而过氧化氢酶和葡萄糖-6-磷酸脱氢酶活性增强,吸入性拟交感神经药的需求减少。
所获得的临床形态学和实验室证据表明,脂质体疗法作为BA基础治疗的替代方法具有很高的疗效。